摘要
胞质-5′-核苷酸酶-Ⅱ(CN-Ⅱ)是迄今为止发现的7种5′-核苷酸酶中的一种,其分布较为广泛,主要以次黄嘌呤核苷酸(IMP)作为其催化底物,兼具有核苷酸水解酶及磷酸转移酶的活性,在维持细胞内核苷酸库的平衡中发挥重要作用。研究发现,CN-Ⅱ与核苷类抗肿瘤药物的耐药有密切关系,其异常表达可直接或间接引起肿瘤细胞对此类药物耐药。如果能以肿瘤细胞中CN-Ⅱ及其他相关耐药因子的表达情况作为临床用药的参考依据,对于提高化疗效果、实现个体化治疗具有重要意义;另外肿瘤细胞中CN-Ⅱ的表达水平亦可做为判断接受核苷类药物化疗的患者预后指标之一。
Cytosolic 5＇ - nucleotidase Ⅱ （CN- Ⅱ ） is ubiquitous enzyme that dephosphorylates inosine monophosphate （IMP） specifically. Seven 5＇ - nucleotidases have been described including CN - Ⅱ so far. This enzyme presents both phosphatase and phosphotransferase activities that are significant in balancing cytosol- ic nucleotide pools. Novel expression of CN - Ⅱ directly or indirectly correlates with resistance of nucleotide analogs in cancer treatment. CN- Ⅱ expression levels may be used to guide the choice of cancer therapy and can be a prognostic factor in patients treated with nucleotide analogs.
出处
《癌症进展》
2006年第5期447-451,共5页
Oncology Progress
